News

Positive Results for AstraZeneca's Treatment of Eosinophilic Granulomatosis with Polyangiitis

James L. Flint

• September 11, 2023

Pharmaceutical company AstraZeneca announced on Monday that a Phase 3 trial of its treatment for eosinophilic granulomatosis with polyangiitis (EGPA) has successfully met its primary endpoint. EGPA is a rare form of vasculitis characterized by inflammation of small to medium-sized blood vessels.

AstraZeneca's treatment, known as Fasenra, not only achieved its primary endpoint but also demonstrated non-inferior rates of remission when compared to mepolizumab, the only approved treatment for EGPA currently available. This is promising news for patients suffering from this rare disease.

EGPA often leads to a development of asthma in about half of the patients affected. Moreover, the disease can cause significant damage to vital organs, making effective treatment crucial for patients' well-being.

Fasenra has received orphan drug designation from the U.S. Food and Drug Administration specifically for the treatment of EGPA. Meanwhile, AstraZeneca confirms that the safety and tolerability profile of Fasenra displayed in the trial aligns with its existing profile.

The complete findings of the trial will be presented at an upcoming medical meeting, providing further insights and information regarding this breakthrough treatment option.